Cessation of Animal Neurovirulence Testing for Novel OPV2: A Review of Supporting Evidence with Supplemental Analyses
Year: 2026
Type: preprint
Abstract: Animal neurovirulence tests have historically been required for release of live oral polio vaccine virus seeds and monovalent bulks (which are intermediates in the production of vaccine lots) because of the demonstrated instability of attenuated phenotype. The improvement in knowledge about the genetics of attenuation, the development and application of high-throughput sequencing, and the advancement of vaccine strains genetically engineered to improve the stability of attenuated phenotype allows this requirement to be revisited considering the latest OPV Technical Report Series guidance from the World Health Organization. This review summarizes evidence from published literature and provides incremental results and analyses which collectively support the position that routine animal neurovirulence testing on novel type 2 oral polio vaccines should not be required. That is, the test does not contribute meaningfully to ensuring the safety of the vaccine when a validated, whole-genome high-throughput sequencing method is included in lot release and other standard production controls are in place. Evidence summarized and evaluated includes pre-clinical research studies, results from clinical research, genetic characterization from surveillance accompanying real-world usage, and characterization of manufacturing vaccine seeds and lots.
Source: Preprints.org
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Keywords: whole genome sequencing, vaccine safety
Open Access status: green
OpenAlex ID: W7236831236
